CClinicalTrials.gg
CompletedNCT04431323ESPRIMOUpdated Feb 2, 2023

Intervention for Young Adults With Multiple Sclerosis

An interventional study of ESPRIMO in Multiple Sclerosis, sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Completed at 1 site in Italy. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Azienda Ospedaliera Universitaria Integrata Verona · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study aims to develop - in collaboration with patients with multiple sclerosis (MS)- a psychosocial and physical activity intervention (i.e., ESPRIMO intervention) for young adults with MS targeted at improving patients' health-related quality of life (HRQoL). Further, the study seeks to preliminarily test the effect, feasibility, and acceptability of the ESPRIMO intervention using a pilot sample of young adults with MS.

Given that the ESPRIMO study will be conducted immediately after the COVID-19 emergency, it does not seem reasonable to start the co-creation of the intervention without taking into account the potential impact of this pandemic on the quality of life and well-being of patients with MS and on their management of care. Thus, the investigators seek to better understand the needs of the target population under these particular circumstances.

Read the detailed description

Being the most common neurological disease causing disability in young adults, multiple sclerosis (MS) does not only impair physical functions but is also often associated with fatigue, symptoms of depression and anxiety as well as reduced health related quality of life (HRQoL). Especially the first years after the diagnosis can be emotionally challenging and psychological adjustment problematic. Since MS is generally detected between the ages of 20 and 40, a period of great significance for professional and personal development, the adaptation to this chronic disease may become even more challenging.

It is now well established that psychological interventions aiming to support people with MS (e.g., Cognitive Behavioural Therapy, mindfulness-based interventions) do not only have a positive effect on psychological aspects, such as resilience, but also on physiological outcomes (e.g., fatigue, physical vitality) and on the perception of general health.

According to the literature, psychological well-being and HRQoL can be also promoted by regular physical activity and exercise (e.g., walking, ballroom dancing), which present the additional advantage of reducing some physical symptoms of MS. Practicing physical activity in groups enables participants also to socialize and create interpersonal relationships, which in turn may significantly affect patients' psychological well-being and illness perception.

Despite the positive impact of interventions focusing on either physical, psychological or social/interpersonal dimensions, there has been little discussion about the development of comprehensive interventions based on the bio-psycho-social model of disease. Even less attention has been paid to the development of early interventions tailored to young adults' needs and to the engagement of patients in the creation of such programs despite the fact that patient engagement has become a central priority for researchers and policy makers in medicine.

Therefore, the investigators aim to develop - in collaboration with patients with MS - a psychosocial and motor intervention (i.e., ESPRIMO intervention) for young adults with MS targeted at improving patients' HRQoL. Further, the study seeks to preliminarily test the effect, feasibility, and acceptability of the ESPRIMO intervention using a pilot sample of young adults with MS.

In the so-called co-creation phase, the primary aim is to create, together with patients, a bio-psycho-social intervention, following also the preferences and suggestions of healthcare professionals. In the intervention phase, the primary aim is to explore the feasibility of the intervention and its effect in improving their quality of life.

Secondary aims of the study are five-fold: 1) to collect patients' opinions and needs as well as healthcare professionals' perspectives on the preferred characteristics of a bio-psycho-social intervention; 2) to explore the effect of the bio-psycho-social intervention in improving bio-psycho-social aspects, such as quality of life, resilience, fatigue (see primary and secondary outcomes) 3) to investigate potential relationships between these psychological variables at baseline and post-intervention; 4) to assess the differences in effect, patient satisfaction and participation rates according to sociodemographic and clinical characteristics; 5) to examine the reasons for dropouts and possible barriers to participation.

Additionally, considering that the ESPRIMO Study will start shortly after the end of the COVID-19 emergency, the potential impact of this emergency on patients' well-being and quality of life must be taken into account when creating the intervention together with the patients.

Therefore, the investigators aim to explore in a pre-phase the potential impact of the COVID-19 emergency on the psychological status and management of disease and the potential positive resources used to deal with this highly challenging situation.

02

Conditions studied

  • Multiple Sclerosis

Keywords

  • quality of life
  • young adults
  • biopsychosocial intervention
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's enrollment of 53 is close to the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Azienda Ospedaliera Universitaria Integrata Verona is the lead sponsor of 92 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

As different samples of patients and healthcare professionals will be enrolled in the different phases of the studies, inclusion and exclusion criteria vary:

  1. Explorative pre-phase "Exploring the psychological impact of the COVID-19 emergency"

    Inclusion Criteria:

    • age range: 18-45 years;
    • MS Diagnosis;
    • Italian speakers;
    • electronic informed consent signed.

    Exclusion Criteria:

    • N/A
  2. Co-creation phase - Survey with young adults with MS

    Inclusion Criteria:

    • age range: 18-45 years;
    • MS diagnosis;
    • Italian speakers;
    • electronic informed consent signed.

    Exclusion Criteria:

    -N/A

  3. Co-creation phase - Survey with Healthcare Providers

    Inclusion Criteria:

    • being a healthcare professional working with MS patients;
    • Italian speakers;
    • electronic informed consent signed.

    Exclusion Criteria:

    -N/A

  4. Co-creation phase - Focus groups

    Inclusion Criteria:

    • age range: 18-45 years;
    • MS diagnosis;
    • Italian speakers;
    • signed informed consent.

    Exclusion Criteria:

    -N/A

  5. Intervention phase

Inclusion Criteria:

  • age range: 18-45 years;
  • Ms diagnosis according to the revised McDonald Criteria [Thompson et al., 2018];
  • Italian speakers;
  • Signed informed consent.

Exclusion Criteria:

  • clinically relevant cognitive deficits as evaluated by the treating neurologist which may represent obstacles in filling the questionnaires and participating in the intervention;
  • severe psychiatric disorders, such as psychosis, bipolar disorder, active substance abuse problems, dissociative disorders, or a current diagnosis of major depression as evaluated by the neurologist or the clinical psychologist;
  • clinically relevant physical impairments rendering impossible the physical activities included in the intervention, defined as an Expanded Disability Status Scale (EDSS) score higher than 3.5 [Bowen et al., 2001].
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    biopsychosocial intervention

    Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters). \[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group. One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.\]

    Behavioral: ESPRIMO

Interventions

  • BehavioralESPRIMO

    Participants will receive the intervention during Phase 2. The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach. The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period. A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Health-related Quality of Life up to 1 week post-intervention

    Health-related Quality of Life at 1 day post-intervention will be Health-related quality of life will be measured by the Italian version of the "Coop/Wonca charts" \[van Weel et al., 1993\] at baseline and 1 day post-intervention assessing the changes between the two time points. The Coop/Wonca questionnaire is a self-reported single-item scale to explore HRQoL, including physical (fitness and daily activities), mental (emotions), social domains (social contacts) and above that general health and change in health status \[Weel et al., 1995\]. Each chart consists of a single question referring to the preceding two weeks and are scored on a 5-level ordinal scale ranging from 1 (no impact) to 5 (high impact), illustrated by a simple picture.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  2. Acceptance and Satisfaction with the Intervention assessed by an ad hoc questionnaire

    An ad hoc questionnaire (one of the two specific outcome measures evaluating the feasibility of the intervention) using closed (rated by Likert scales ranging from 1 (not at all) to 10 (very much, with higher scores reflecting higher levels of acceptance and satisfaction) and open questions will be administered to evaluate the acceptance and satisfaction of participants. Information on participants' experience will inform the intervention and its administration and will reduce barriers to participation for future patients.

    Time frame: T1: up to 1 week post-intervention

Secondary outcomes

  1. Change from Baseline Resilience Features up to 1 week post-intervention

    Resilience will be measured using the Italian version of the "Connor-Davidson Resilience Scale" \[CD-RISC; Connor \& Davidson, 2003\] at baseline and 1 day post-intervention assessing the changes between the two time points. The CD-RISC is designed to assess resilience features in adolescents and adults and composed of 25 items and evaluated on a 5-point Likert scale (ranging from 0 "not true at all" to 4 "true nearly all of the time"), with higher scores reflecting higher levels of resilience.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  2. Change from Baseline Well-being up to 1 week post-intervention

    Well-being will be measured using the Italian version of the "Short Form 12 general health questionnaire" \[SF12, Apolone et al., 2001\] at baseline and 1 day post-intervention assessing the changes between the two time points. The SF12 is a validated 12-item questionnaire with Physical and Mental Component Summary (PCS and MCS, respectively) scores. The SF12 uses different types of scales (e.g., Yes/No questions, scales ranging from 1(always) to 6 (never)).

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  3. Change from Baseline Mindfulness Traits up to 1 week post-intervention

    Mindfulness traits will be assessed using the Italian version of the "Five Facet Mindfulness Questionnaire" \[FFMQ; Baer et al., 2006; Giovannini et al., 2014\] at baseline and 1 day post-intervention assessing the changes between the two time points. The FFMQ-SF is a 24-item self-report questionnaire measuring one general mindfulness factor and five secondary facets (i.e., Observe, Describe, Act with Awareness, Nonjudge, and Nonreact) on a 5-point Likert scale, ranging from 1 ("never or very rarely true") to 5 ("very often or always true"), with higher total scores reflecting a greater degree of mindfulness.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  4. Change from Baseline Self-efficacy in MS up to 1 week post-intervention assessed by the "Self-Efficacy in Multiple Sclerosis Scale" (SEMS)

    Self-efficacy will be measured using the "Self-Efficacy in Multiple Sclerosis Scale" \[SEMS; Bonino et al., 2016\] at baseline and 1 day post-intervention assessing the changes between the two time points. It is a 15-item self-completion instrument using a 5-point Likert scale (from 0 = not at all confident to 4 = very confident). Items are conceptually allocated to two areas: "Goal setting" (9 items) and "Symptom management" (6 items).

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  5. Change from Baseline Perceived Social Support up to 1 week post-intervention

    Perceived social support will be measured using the "Multidimensional Scale of Perceived Social Support" \[MSPSS; Prezza \& Principato, 2002; Zimet et al., 1988\] at baseline and 1 day post-intervention assessing the changes between the two time points. It is a 12-item self-report measure, assessing on a 7-point Likert scale (from 1 "strongly disagree" to 7 "strongly agree") the level of perceived social support of various sources: family, friends, and significant others.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  6. Change from Baseline Levels of Anxiety and Depression up to 1 week post-intervention

    Levels of anxiety and depression will be measured using the "Hospital Anxiety and Depression Scale" \[HADS; Zigmond \& Snaith, 1983; Costantini et al., 1999\] at baseline and 1 day post-intervention assessing the changes between the two time points. The HADS is a brief self-report questionnaire composed of 14 items describing on a 4-point scale from 0 to 3 the levels of anxiety a person is experiencing. HADS anxiety (HADS-A, 7 items) and depression (HADS-D, 7 items) subscale scores will be calculated, possibly ranging from 0 (no symptoms) to 21 (most severe symptoms). A HADS-A and HADS-D score of ≥8 indicates a high risk of anxiety and depressive disorder.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  7. Change from Baseline Illness Representations up to 1 week post-intervention

    Illness perception will be measured using the "Brief Illness Perception Questionnaire" \[Brief IPQ-R; Broadbent et al., 2006; Pain et al., 2006\] at baseline and 1 day post-intervention assessing the changes between the two time points. It is a 9-item self-completion instrument using a 5-point Likert scale (from "strongly disagree" to "strongly agree") providing a quantitative measurement of the components of illness representations \[Leventhal et al., 1984; Leventhal et al., 1997\].

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  8. Change from Baseline Committed Action up to 1 week post-intervention

    The construct of committed action is measured applying the Italian version of the "The Committed Action Questionnaire-8" (CAQ-8) \[McCracken et al., 2015\] at baseline and 1 day post-intervention assessing the changes between the two time points. The CAQ-8, a short version of The Committed Action Questionnaire \[McCracken, 2013\], is an 8-item questionnaire using a 7-point Likert scale (from 0 = never true to 6 = always true).

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  9. Change from Baseline Levels of (Motor and Cognitive) Fatigue up to 1 week post-intervention

    Fatigue will be measured applying the "Fatigue Scale for Motor and Cognitive Functions" \[FSMC; Penner et al., 2009; Elbers et al., 2012\] at baseline and 1 day post-intervention assessing the changes between the two time points. It is a self-report fatigue questionnaires validated in patients with multiple sclerosis (MS) and useful to evaluate both motor and cognitive fatigue. It is composed by 20 items evaluated on a Likert scale, ranging from 1 (it never happens) to 5 (it always happens), with higher scores reflecting higher levels of motor and cognitive fatigue.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  10. Change from Baseline Perceived Autonomy Support up to 1 week post-intervention

    Perceived autonomy support (as part of a set of variables reflecting attitudes towards physical activity and motivation to be physically active) will be measured with the "Perceived Autonomy Support Scale for Exercise Setting" (PASSES; Hagger et al., 2007) at baseline and 1 day post-intervention assessing the changes between the two time points. The 12 items are rated on a 7-point Likert scale ranging from 1(totally disagree) to 7 (totally agree), with higher scores reflecting greater perceptions of autonomy support.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  11. Change from Baseline Autonomous Motivation up to 1 week post-intervention

    Autonomous motivation (as part of a set of variables reflecting attitudes towards physical activity and motivation to be physically active) will be measured with the "Behavioral Regulation in Exercise Questionnaire" \[BREQ-3; Markland et al., 2014\] at baseline and 1 day post-intervention assessing the changes between the two time points. The 24 items are rated on a 5-point Likert scale ranging from 1 (totally disagree) to 5 (totally agree).

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  12. Change from Baseline Attitudes up to 1 week post-intervention

    Attitudes (as part of a set of variables reflecting attitudes towards physical activity and motivation to be physically active) will be measured by a scale developed by Galli et al. \[2018\], following the recommendations of Ajzen \[1991\] at baseline and 1 day post-intervention assessing the changes between the two time points. The scale comprises 6 items with responses provided on seven-points scales (with contrasting adjectives (e.g.,"bad - good", "harmful-beneficial").

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  13. Change from Baseline Subjective Norms up to 1 week post-intervention

    Subjective norms (as part of a set of variables reflecting attitudes towards physical activity and motivation to be physically active) will be measured by a scale developed by Galli et al. \[2018\], following the recommendations of Ajzen \[1991\] at baseline and 1 day post-intervention assessing the changes between the two time points. The 3 items of the scale are rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree), with a greater single score (aggregated item scores) indicating greater normative social pressure toward the behavior.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  14. Change from Baseline Perceived Behavioral Control up to 1 week post-intervention

    Perceived Behavioral Control (as part of a set of variables reflecting attitudes towards physical activity and motivation to be physically active) will be measured by a scale developed by Galli et al. \[2018\], following the recommendations of Ajzen \[1991\] at baseline and 1 day post-intervention assessing the changes between the two time points. The 3 items of the scale are rated on a 7-point Likert scale, with a greater single score (aggregated item scores) indicating greater perceived confidence toward the behavior.

    Time frame: T0: baseline, T1: up to 1 week post-intervention

  15. Change from baseline number of steps/day to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the number of steps/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  16. Change from baseline km traveled/day to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the number of km traveled/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  17. Change from baseline number of active hours/day to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the number of active hours/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  18. Change from baseline number of inactive hours/day to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the number of inactive hours/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  19. Change from Baseline number of hours of sleep/day to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the number of hours of sleep/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  20. Change from baseline heart rate to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the heart rate (HR).

    Time frame: T0: baseline, T1: 5 days post-intervention

  21. Change from baseline heart rate variability to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the heart rate variability (HRV).

    Time frame: T0: baseline, T1: 5 days post-intervention

  22. Change from estimated kilocalories consumed/day at baseline to 5 days post-intervention

    A smartwatch will be used by each patient for 5 days at baseline (T0) and 5 days after the intervention (T1) in order to compare the estimated kilocalories consumed/day.

    Time frame: T0: baseline, T1: 5 days post-intervention

  23. Number of Drop Outs

    The number of drop outs is the second specific outcome measure evaluating the feasibility of the intervention.

    Time frame: T1: up to 1 week post-intervention

  24. Exact Time of Dropping Out

    The exact time point of dropping out will also be assessed.

    Time frame: T1: up to 1 week post-intervention

  25. Underlying Reasons for Dropping Out assessed by an ad hoc questionnaire with open questions

    Patients who drop out during the interventions will be contacted to assess the underlying reasons using an ad hoc questionnaire with open questions.

    Time frame: T1: up to 1 week post-intervention

07

Study locations

1 site
  • Azienda Ospedaliera Universitaria Integrata Verona, Policlinico G.B. Rossi
    Verona, Veneto 37134, Italy
08

References and documents

Publications

  • Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. PubMed 29275977 ↗
  • Bowen J, Gibbons L, Gianas A, Kraft GH. Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler. 2001 Jun;7(3):201-6. doi: 10.1177/135245850100700311. PubMed 11475445 ↗
  • Van Weel C. Functional status in primary care: COOP/WONCA charts. Disabil Rehabil. 1993 Apr-Jun;15(2):96-101. doi: 10.3109/09638289309165878. PubMed 8513163 ↗
  • Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82. doi: 10.1002/da.10113. PubMed 12964174 ↗
  • Apolone G, Mosconi P, Quattrociocchi L, et al. Questionario sullo stato di salute SF-12. Versione italiana. Milano: Guerini e Associati, 2001.
  • Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006 Mar;13(1):27-45. doi: 10.1177/1073191105283504. PubMed 16443717 ↗
  • Giovannini C, Giromini L, Bonalume L, et al. The Italian Five Facet Mindfulness Questionnaire: A Contribution to its Validity and Reliability. J Psychopathol Behav Assess 2014; 36.doi: 10.1007/s10862-013-9403-0.
  • Bonino S, Graziano F, Borghi M, et al. The Self-Efficacy in Multiple Sclerosis (SEMS) Scale: Development and Validation With Rasch Analysis. European Journal of Psychological Assessment. 2015; doi: 10.1027/1015-5759/a000350.
  • Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999 May;7(3):121-7. doi: 10.1007/s005200050241. PubMed 10335929 ↗
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. PubMed 6880820 ↗
  • Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006 Jun;60(6):631-7. doi: 10.1016/j.jpsychores.2005.10.020. PubMed 16731240 ↗
  • Pain D, Miglioretti M, Angelino, E. Development of Italian version of brief-IPQ (Illness perception questionnaire, short version), a method for assessing the illness representations. Psicologia della Salute. 2006. 81-89.
  • Leventhal H, Nerenz DR, Steele DS. Illness representations and coping with health threats. In: Baum, A. Taylor, S.E. and Singer, J.E. (Eds.), Handbook of psychology and health. Vol. IV. pp. 219-252. Hillsdale, NJ: Erlbaum, 1984.
  • Leventhal H, Benyamini Y, Brownlee S, et al. Illness representations: Theoretical foundations. In K. J. Petrie & J. A. Weinman (Ed.), Perceptions of health and illness: Current research and applications (p. 19-45). Reading, UK: Harwood Academic Publishers, 1997.
  • McCracken LM. Committed action: an application of the psychological flexibility model to activity patterns in chronic pain. J Pain. 2013 Aug;14(8):828-35. doi: 10.1016/j.jpain.2013.02.009. Epub 2013 May 4. PubMed 23651881 ↗
  • McCracken LM, Chilcot J, Norton S. Further development in the assessment of psychological flexibility: a shortened Committed Action Questionnaire (CAQ-8). Eur J Pain. 2015 May;19(5):677-85. doi: 10.1002/ejp.589. Epub 2014 Sep 2. PubMed 25181605 ↗
  • Penner IK, Raselli C, Stocklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler. 2009 Dec;15(12):1509-17. doi: 10.1177/1352458509348519. Epub 2009 Dec 7. PubMed 19995840 ↗
  • Elbers RG, Rietberg MB, van Wegen EE, Verhoef J, Kramer SF, Terwee CB, Kwakkel G. Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Qual Life Res. 2012 Aug;21(6):925-44. doi: 10.1007/s11136-011-0009-2. Epub 2011 Oct 20. PubMed 22012025 ↗
  • Prezza M, Principato MC. La rete e il sostegno sociale. In: Prezza M, Santinello M, eds. Conoscere la comunit . Bologna. Italy: Il Mulino, 2002: 193-233.
  • Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Winter;55(3-4):610-7. doi: 10.1080/00223891.1990.9674095. PubMed 2280326 ↗
  • Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes. 1991;50:179- 211.
  • Galli F, Chirico A, Mallia L, Girelli L, De Laurentiis M, Lucidi F, Giordano A, Botti G. Active lifestyles in older adults: an integrated predictive model of physical activity and exercise. Oncotarget. 2018 May 22;9(39):25402-25413. doi: 10.18632/oncotarget.25352. eCollection 2018 May 22. PubMed 29875997 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data for the primary and secondary outcome measures will be made available upon reasonable request.

Supporting information: Study protocol, Sap, Icf, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04431323
Lead sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
May 13, 2020
Primary completion
Jul 30, 2022
Completion
Oct 30, 2022
Last update
Feb 2, 2023

Study contacts

Michela Rimondini
principal investigator · Azienda Ospedaliera Universitaria Integrata Verona
Alberto Gajofatto Study Principal Investigator
principal investigator · Azienda Ospedaliera Universitaria Integrata Verona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion